Jinxin Reproductive Investment

Jinxin Reproductive Investment specializes in advanced assisted reproductive technology (ART) services, primarily in-vitro fertilization (IVF) and intrauterine insemination (IUI). The company integrates sophisticated technology, including AI-driven embryo selection, advanced Preimplantation Genetic Testing, and automated incubation systems, to enhance treatment efficacy and patient outcomes across its network.

Founded in 2003 by Dr. Zhong Ying and experienced reproductive clinicians, the company originated as Chengdu Xinan Gynecological Hospital. Their insight was the significant, unmet demand for specialized infertility treatments in China, which public hospitals could not adequately address. This led to establishing a dedicated, patient-focused ART center emphasizing personalized care.

Jinxin Reproductive Investment serves individuals and couples seeking fertility solutions in China and internationally. The company envisions evolving beyond core ART offerings to build a comprehensive women's health ecosystem. This includes expanding into prenatal, obstetric, and postpartum care, providing integrated support throughout women's reproductive health journeys.